Evidence map›Paper›PMID 26039236›Full record

ArticleInternational journal of molecular sciences2015

Hyperactive RAS/PI3-K/MAPK Signaling Cascade in Migration and Adhesion of Nf1 Haploinsufficient Mesenchymal Stem/Progenitor Cells.

Yuan Zhou, Yongzheng He, Richa Sharma, Wen Xing, Selina A Estwick, Xiaohua Wu, Steven D Rhodes, Mingjiang Xu, Feng-Chun Yang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Deletion of p18Stem cell research & therapy · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yuan ZhouState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China. yuanzhou@ihcams.ac.cn.
Yongzheng HeDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. yonhe@iu.edu.
Richa SharmaHerman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA. ricsharm@iupui.edu.
Wen XingState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China. xw2318@aliyun.com.
Selina A EstwickDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. selinaorlando@yahoo.com.
Xiaohua WuDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. wu_xiaohua@lilly.com.
Steven D RhodesHerman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA. sdrhodes@iupui.edu.
Mingjiang XuDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. mx2@iupui.edu.
Feng-Chun YangDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. fyang@iu.edu.
Indiana University School of MedicineIndiana University – Purdue University Indianapolis · USChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

Indiana Medical Scientist/Engineer Training ProgramT32GM077229 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI GASTON, BENJAMIN, HERBERT, BRITTNEY-SHEA · 2008 to 2022
$6.0M
NIGMS NIH HHS T32 GM077229
6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease caused by mutations in the NF1 tumor suppressor gene, which affect approximately 1 out of 3000 individuals. Patients with NF1 suffer from a range of malignant and nonmalignant manifestations such as plexiform neurofibromas and skeletal abnormalities. We previously demonstrated that Nf1 haploinsufficiency in mesenchymal stem/progenitor cells (MSPCs) results in impaired osteoblastic differentiation, which may be associated with the skeletal manifestations in NF1 patients. Here we sought to further ascertain the role of Nf1 in modulating the migration and adhesion of MSPCs of the Nf1 haploinsufficient (Nf1(+/-)) mice. Nf1(+/-) MSPCs demonstrated increased nuclear-cytoplasmic ratio, increased migration, and increased actin polymerization as compared to wild-type (WT) MSPCs. Additionally, Nf1(+/-) MSPCs were noted to have significantly enhanced cell adhesion to fibronectin with selective affinity for CH271 with an overexpression of its complimentary receptor, CD49e. Nf1(+/-) MSPCs also showed hyperactivation of phosphoinositide 3-kinase (PI3-K) and mitogen activated protein kinase (MAPK) signaling pathways when compared to WT MSPCs, which were both significantly reduced in the presence of their pharmacologic inhibitors, LY294002 and PD0325901, respectively. Collectively, our study suggests that both PI3-K and MAPK signaling pathways play a significant role in enhanced migration and adhesion of Nf1 haploinsufficient MSPCs.

Indexed as

HaploinsufficiencyMAP Kinase Signaling SystemActinsAnimalsBenzamidesCell AdhesionCell MovementCells, CulturedChromonesDiphenylamineMesenchymal Stem CellsMiceMorpholinesNeurofibromin 1Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase Inhibitors2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneActinsBenzamidesChromonesDiphenylaminemirdametinibMorpholinesNeurofibromin 1Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase Inhibitorsras Proteinsmesenchymal stem/progenitor cellsneurofibromaneurofibromatosis 1oncogene protein p21 (ras)

Identifiers

PMID26039236
PMCPMC4490447
OpenAlexW2132157372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.